Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PAVA
- Development stage
- Discontinued
- Lead developer
- Adjuvance Technologies
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**PAVA** is an investigational acellular pertussis vaccine product adjuvanted with TQL-1055, a semisynthetic saponin adjuvant developed by Adjuvance Technologies. It is intended to prevent pertussis caused by *Bordetella pertussis* by enhancing immune responses to acellular pertussis vaccine antigens. PAVA was evaluated in a randomized, double-blind, active-controlled Phase 1 dose-escalation study in adults; the registered study was subsequently terminated because of financial constraints. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04793620))
- Other names
- Pertussis Acellular Vaccine Adjuvanted With TQL1055
Beyond the preview
Go deeper on PAVA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PAVA.